secwatch.observer — SEC 8-K summary
======================================

Issuer:     OPKO HEALTH, INC. (OPK)
CIK:        0000944809
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001437749-24-025180
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OPKO reports Q2 net loss $10.3M; enters $250M note deal, plans $100M buyback
----------------------------------------------------------------------------

- Q2 total revenues $182.2M (down from $265.4M YoY); operating loss $61.7M vs income $7.0M; net loss $0.01/share.
- NGENLA global launch ongoing; earned $6.3M gross profit share from Pfizer in Q2 (up from $3.8M).
- Entered $250M note purchase agreement with HealthCare Royalty secured by NGENLA profit share; retains milestone upside.
- Board authorized $100M share repurchase program (~10.1% of shares outstanding).
- Sale of BioReference laboratory assets to Labcorp for $237.5M expected close end of Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/944809/000143774924025180/0001437749-24-025180-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/944809/000143774924025180/opk20240801_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-025180

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer